Mar 28, 2017 - GAP-f Partners ... build on the experience of PHTI partners and be hosted by ... Exploring favourable opt
The Global Accelerator for Paediatric Formulations (GAPf): Updated framework for collaboration GAP-f Partners Geneva March 28th, 2017
The Global accelerator for Paediatric formulations This is NOT a new initiative! It is a critical component of the global efforts to reach super fast-track targets for children and adolescents (AIDS Free) The Global accelerator is a collaboration framework supported by an innovative financing mechanisms to fast track development of paediatric formulations This collaboration framework builds on existing efforts and aims to promote a faster, more efficient and more focused approach to paediatric formulation development.
Developing and delivering paediatric formulations through collaborative and coordinated action PADO
PROGRAMS
Priority formulations are reliably supplied to countries
Key formulations are prioritised in the context of a public health approach PAWG
Drug optimization PHTI
PAPWG
Priority formulations are procured via a pooled mechanism
IATT
Technical/research work is undertaken to support development of the priority formulations
Priority formulations are included in optimal formulary for selection
Developing and delivering paediatric formulations through collaborative and coordinated action Clinical work Development and introduction
PADO
PROGRAMS
Priority formulations are reliably supplied to countries
Key formulations are prioritised in the context of a public health approach PAWG
Drug optimization PHTI
PAPWG
Priority formulations are procured via a pooled mechanism
IATT
Technical/research work is undertaken to support development of the priority formulations
Priority formulations are included in optimal formulary for selection
Global Accelerator helps us to simplify Prioritisation (PADO/PAWG)
Development and introduction of priority products
Global Accelerator helps us to simplify Development and introduction of priority products
Prioritisation (PADO/PAWG)
UPSTREAM
Development
GAPf
Regulatory (NRAs)
DOWNSTREAM
Introducti on
Research
Regulatory (SRAs)
Procurement
Proposed staged approach: GAPf development and implementation
1. Activities that require little or no additional funding, but advance the Global Accelerator agenda.
2. Global Accelerator will leverage existing investments,
build on the experience of PHTI partners and be hosted by an organization to be determined .
3. Full development of the Global Accelerator
with broad focus on paediatric formulation to be included in existing PPP or as an independent entity. (Pending successful completion of stage 1 and 2)
Proposed recommendations by FDA/EMA to Innovators of ARVs • Engage with WHO PAWG at early stage • Use weight-based dosing in designing paediatric pharmacokinetic (PK) and safety studies. • Include adolescents in initial registrational adult efficacy trials or in parallel with adult studies. • For new drugs in development, begin paeds formulation as soon as there is evidence of potential public Ongoing health benefit for people living with HIV. conversation • Enroll all ages/weight bands concurrently (>4 weeks) with SRAs and other • Ensure acceptability and palatability data key • Initial PSP/PIP submission can be less detailed and regulatory process for subsequent revisions can be simplified agencies and streamlined,
Revised Role and Membership for PAWG • To be the a reference group to provide overall technical advice (clinical/PK/programmatic) to drug and formulation development • To have a formal role in advising manufacturers on the development of their PIPs/PSPs • To contribute to the PK work required for informing ratio and dosing for FDCs
• Broader set of skills • Greater responsiveness • Greater accountability • More transparency • Ensure continuity and sustainability Inclusion of Pregnancy!
Research toolkit for formulation development
Improving paediatric “forecasting”
HIV infected children
HIV infected children diagnosed
HIV infected children started on ART
HIV infected children failing 1st line
HIV infected Switched to 2nd line
GAPf will build on the lessons learnt from PHTI The Paediatric HIV Treatment Initiative was convened by UNITAID and launched in 2014 to: Ensure intellectual property and knowledge sharing Ensure technical guidance from WHO experts translates into real medicines Engage with industry and support formulation development Provide a platform for the different partners to work together
CHAI-UNITAID project a proof of concept…
Full genesis of the GAPf Building upon the experience and lessons learnt from HIV the Global Accelerator will move into other orphaned medications and other disease areas (ie hepatitis, tuberculosis and other infectious diseases) This stage will require substantial funding commitment, fully defined accountability and sustainability plan as well as a functional structure that could be hosted by an existing partners organization or a consortium of partners. Full vision currently being discuss!
Evolution and Next Steps • Proposal under review by the leadership of partner organizations: to be circulated to the broader group of stakeholders, by May 2017. • White paper for further dissemination of the concept • Implementation and monitor progress of stage 1 activities: quarterly progress update to AIDS Free working group. • Fully defining the set up of stage 2 and potential additional activities • Additional consultation with manufacturers to better articulate the key financial interventions required • Exploring favourable options for the genesis of the Global Accelerator and his